|
|
 |
|
Viewing report
|
|
|
|
Menarini: PharmaVitae Profile
Datamonitor, June 2010, Pages: 48
Introduction
This analysis examines the historical and forecast performance for Menarini in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Menarini's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Menarini over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Menarini's performance against key rivals in the prescription pharmaceutical sector
- Discover how the company's business model continues to drive sales growth across the established and emerging European markets
- Assess Menarini's position in the hypertension market and the various challenges that its broad antihypertensive portfolio could face
Customers who bought this item also bought
Boehringer Ingelheim GmbH: PharmaVitae Profile
Johnson & Johnson: PharmaVitae Profile
Forest Laboratories Inc.: PharmaVitae Profile
UCB S.A.: PharmaVitae Profile
Chugai Pharmaceutical Co., Ltd: PharmaVitae Profile
Baxter International Inc.: PharmaVitae Profile
Celgene Corporation: PharmaVitae Profile
Actelion Ltd: PharmaVitae Profile
Warner-Chilcott Plc: PharmaVitae Profile
Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile
|
|
|
|
